{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:24:07Z","timestamp":1783009447286,"version":"3.54.5"},"reference-count":130,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Guangdong Medical Research Fund Program","award":["A2025176 and B2025153"],"award-info":[{"award-number":["A2025176 and B2025153"]}]},{"name":"Guangdong University Youth Innovation Talent Project","award":["2024KQNCX307"],"award-info":[{"award-number":["2024KQNCX307"]}]},{"name":"Guangdong Provincial Bureau of Traditional Chinese Medicine Program","award":["20251445"],"award-info":[{"award-number":["20251445"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2687714","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:12:42Z","timestamp":1783008762000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Selective targeting phosphodiesterase-5 (PDE5): clinical progress, design strategies, and emerging prospects"],"prefix":"10.1080","volume":"41","author":[{"given":"Yanhong","family":"Li","sequence":"first","affiliation":[{"name":"Guangdong Jiangmen Chinese Medicine College","place":["Jiangmen, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University","place":["Guangzhou, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkao","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University","place":["Guangzhou, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangmen Central Hospital","place":["Jiangmen, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiliang","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University","place":["Guangzhou, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4228"},{"issue":"10","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie GS","year":"2019","unstructured":"Baillie GS, Tejeda GS, Kelly MP. Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019;18(10):770\u2013796.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis SH","year":"2011","unstructured":"Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011;91(2):651\u2013690.","journal-title":"Physiol Rev"},{"issue":"19","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1021\/acs.jmedchem.9b02170","article-title":"Advances in development of phosphodiesterase-4 inhibitors","volume":"63","author":"Peng T","year":"2020","unstructured":"Peng T, Qi B, He J, Ke H, Shi J. Advances in development of phosphodiesterase-4 inhibitors. J Med Chem. 2020;63(19):10594\u201310617.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014still expanding after half a century","volume":"3","author":"Beavo JA","year":"2002","unstructured":"Beavo JA, Brunton LL. Cyclic nucleotide research\u2014still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3(9):710\u2013718.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti M","year":"2007","unstructured":"Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76(1):481\u2013511.","journal-title":"Annu Rev Biochem"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.322264"},{"issue":"3","key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.pharmr.2025.100042","article-title":"Cyclic nucleotide phosphodiesterases as drug targets","volume":"77","author":"Kelly MP","year":"2025","unstructured":"Kelly MP, Nikolaev VO, Gobejishvili L, Lugnier C, Hesslinger C, Nickolaus P, Kass DA, Pereira de Vasconcelos W, Fischmeister R, Brocke S, et al. Cyclic nucleotide phosphodiesterases as drug targets. Pharmacol Rev. 2025;77(3):100042.","journal-title":"Pharmacol Rev"},{"issue":"13","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel phosphodiesterase inhibitors for cognitive improvement in Alzheimer\u2019s disease","volume":"61","author":"Wu Y","year":"2018","unstructured":"Wu Y, Li Z, Huang YY, Wu D, Luo HB. Novel phosphodiesterase inhibitors for cognitive improvement in Alzheimer\u2019s disease. J Med Chem. 2018;61(13):5467\u20135483.","journal-title":"J Med Chem"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"105104","DOI":"10.1016\/j.bioorg.2021.105104","article-title":"Design, synthesis and biological evaluation of novel pyrazolopyrimidinone derivatives as potent PDE1 inhibitors","volume":"114","author":"Zhang B","year":"2021","unstructured":"Zhang B, Huang Y, Zhang SR, Huang MX, Zhang C, Luo HB. Design, synthesis and biological evaluation of novel pyrazolopyrimidinone derivatives as potent PDE1 inhibitors. Bioorg Chem. 2021;114:105104.","journal-title":"Bioorg Chem"},{"issue":"5","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis T","year":"2012","unstructured":"Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol. 2012;165(5):1288\u20131305.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo JA.","year":"1995","unstructured":"Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725\u2013748.","journal-title":"Physiol Rev"},{"issue":"13","key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors \u2013 pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson KE.","year":"2018","unstructured":"Andersson KE. PDE5 inhibitors \u2013 pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554\u20132565.","journal-title":"Br J Pharmacol"},{"issue":"49","key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"38149","DOI":"10.1074\/jbc.M110.141614","article-title":"Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain","volume":"285","author":"Wang H","year":"2010","unstructured":"Wang H, Robinson H, Ke H. Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. J Biol Chem. 2010;285(49):38149\u201338156.","journal-title":"J Biol Chem"},{"issue":"33","key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"22749","DOI":"10.1074\/jbc.M801577200","article-title":"Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change","volume":"283","author":"Heikaus CC","year":"2008","unstructured":"Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA, Klevit RE. Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol Chem. 2008;283(33):22749\u201322759.","journal-title":"J Biol Chem"},{"issue":"9","key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications","volume":"1","author":"Rotella DP.","year":"2002","unstructured":"Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov. 2002;1(9):674\u2013682.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Nagendran J","year":"2007","unstructured":"Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116(3):238\u2013248.","journal-title":"Circulation"},{"issue":"5","key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro","volume":"83","author":"Wallis RM","year":"1999","unstructured":"Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C\u201312C.","journal-title":"Am J Cardiol"},{"issue":"1","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/sj.ijir.3901207","article-title":"Tissue expression, distribution, and regulation of PDE5","volume":"16","author":"Lin CS.","year":"2004","unstructured":"Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res. 2004;16(Suppl. 1):S8\u2013S10.","journal-title":"Int J Impot Res"},{"issue":"30","key":"e_1_3_3_21_1","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.2174\/138161209789206971","article-title":"PDE5 inhibitors: in vitro and in vivo pharmacological profile","volume":"15","author":"Kouvelas D","year":"2009","unstructured":"Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des. 2009;15(30):3464\u20133475.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-pharmtox-040122-034745","article-title":"Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders","volume":"63","author":"Samidurai A","year":"2023","unstructured":"Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annu Rev Pharmacol Toxicol. 2023;63(1):585\u2013615.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.RES.0000178451.08719.5b","article-title":"Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria","volume":"97","author":"Costa AD","year":"2005","unstructured":"Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, Critz SD. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res. 2005;97(4):329\u2013336.","journal-title":"Circ Res"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mce.2016.01.015","article-title":"Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: studies in rabbits","volume":"424","author":"Maneschi E","year":"2016","unstructured":"Maneschi E, Cellai I, Aversa A, Mello T, Filippi S, Comeglio P, Bani D, Guasti D, Sarchielli E, Salvatore G, et al. Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: studies in rabbits. Mol Cell Endocrinol. 2016;424:50\u201370.","journal-title":"Mol Cell Endocrinol"},{"key":"e_1_3_3_25_1","first-page":"961","article-title":"Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis","volume":"61","author":"Piazza GA","year":"2001","unstructured":"Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WEJr, Klein-Szanto AJ, Farnell DR, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001;61:961\u20133968.","journal-title":"Cancer Res"},{"issue":"12","key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita K","year":"2009","unstructured":"Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, et al. Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009;58(12):2880\u20132892.","journal-title":"Diabetes"},{"issue":"8","key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tips.2014.05.003","article-title":"Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond","volume":"35","author":"Lukowski R","year":"2014","unstructured":"Lukowski R, Krieg T, Rybalkin SD, Beavo J, Hofmann F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol Sci. 2014;35(8):404\u2013413.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0167-4889(01)00086-6","article-title":"Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain","volume":"1539","author":"Giordano D","year":"2001","unstructured":"Giordano D, De Stefano ME, Citro G, Modica A, Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta. 2001;1539(1\u20132):16\u201327.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0149-2918(98)80103-3","article-title":"Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction","volume":"20","author":"Goldenberg MM.","year":"1998","unstructured":"Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther. 1998;20(6):1033\u20131048.","journal-title":"Clin Ther"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422407"},{"issue":"9","key":"e_1_3_3_31_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrd898","article-title":"Erectile-dysfunction therapies","volume":"1","author":"Renaud RC","year":"2002","unstructured":"Renaud RC, Xuereb H. Erectile-dysfunction therapies. Nat Rev Drug Discov. 2002;1(9):663\u2013664.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bmc.2011.10.022","article-title":"The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics","volume":"20","author":"Rawson DJ","year":"2012","unstructured":"Rawson DJ, Ballard S, Barber C, Barker L, Beaumont K, Bunnage M, Cole S, Corless M, Denton S, Ellis D, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012;20(1):498\u2013509.","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"e_1_3_3_33_1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMc053442","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"354","author":"Izbicki G","year":"2006","unstructured":"Izbicki G, Rosengarten D, Picard E. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2006;354(10):1091\u20131093.","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_3_3_34_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani HA","year":"2006","unstructured":"Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689\u2013702.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14656561003698131","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction","volume":"11","author":"Dorsey P","year":"2010","unstructured":"Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11(7):1109\u20131122.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"e_1_3_3_36_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1753465812463627","article-title":"Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension","volume":"7","author":"Udeoji DU","year":"2013","unstructured":"Udeoji DU, Schwarz ER. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis. 2013;7(1):39\u201349.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","article-title":"Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction","volume":"58","author":"Stief C","year":"2004","unstructured":"Stief C, Porst H, S\u00e1enz De Tejada I, Ulbrich E, Beneke M, Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract. 2004;58(3):230\u2013239.","journal-title":"Int J Clin Pract"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02358.x"},{"issue":"4","key":"e_1_3_3_39_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein I","year":"2012","unstructured":"Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, Trask B, Day WW. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122\u20131133.","journal-title":"J Sex Med"},{"issue":"8","key":"e_1_3_3_40_1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ijcp.12074","article-title":"PDE5 inhibitors: considerations for preference and long-term adherence","volume":"67","author":"Smith WB","year":"2013","unstructured":"Smith WB2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67(8):768\u2013780.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"e_1_3_3_41_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1756287215625408","article-title":"A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction","volume":"8","author":"Cho MC","year":"2016","unstructured":"Cho MC, Paick JS. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. Ther Adv Urol. 2016;8(2):100\u2013117.","journal-title":"Ther Adv Urol"},{"issue":"5","key":"e_1_3_3_42_1","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/j.1743-6109.2010.01711.x","article-title":"Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial","volume":"7","author":"Glina S","year":"2010","unstructured":"Glina S, Fonseca GN, Bertero EB, Dami\u00e3o R, Rocha LC, Jardim CR, Cairoli CE, Teloken C, Torres LO, Faria GE, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med. 2010;7(5):1928\u20131936.","journal-title":"J Sex Med"},{"issue":"8","key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jsxmed\/qdaf109","article-title":"Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial","volume":"22","author":"Yang Y","year":"2025","unstructured":"Yang Y, Zhang X, Jiang T, Zhao L, Li F, Yao W, Deng J, Zhang X, Yang J, Ji Z, et al. Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial. J Sex Med. 2025;22(8):1430\u20131439.","journal-title":"J Sex Med"},{"issue":"1","key":"e_1_3_3_44_1","doi-asserted-by":"crossref","first-page":"qfae008","DOI":"10.1093\/sexmed\/qfae008","article-title":"Safety, tolerability, and pharmacokinetics of sildenafil citrate tablets, a novel oral PDE5 inhibitor, in healthy Chinese volunteers after multiple-dose administration","volume":"12","author":"Xie R","year":"2024","unstructured":"Xie R, Jia B, Cheng L, Zhao N, He X, Wang X, Zhao X, Cui Y. Safety, tolerability, and pharmacokinetics of sildenafil citrate tablets, a novel oral PDE5 inhibitor, in healthy Chinese volunteers after multiple-dose administration. Sex Med. 2024;12(1):qfae008.","journal-title":"Sex Med"},{"issue":"2","key":"e_1_3_3_45_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/andr.70083","article-title":"Pharmacokinetics, pharmacodynamics, and safety interaction study of tunodafil hydrochloride and alcohol: a randomized, blinded, placebo-controlled, three-cycle crossover study in Chinese healthy men","volume":"14","author":"Hu D","year":"2026","unstructured":"Hu D, Niu S, Huang F, Jin L, Gu Q, Li Y, Lee C, Xie Z, Liu X, Men F, et al. Pharmacokinetics, pharmacodynamics, and safety interaction study of tunodafil hydrochloride and alcohol: a randomized, blinded, placebo-controlled, three-cycle crossover study in Chinese healthy men. Andrology. 2026;14(2):466\u2013479.","journal-title":"Andrology"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01491-7"},{"key":"e_1_3_3_47_1","unstructured":"Jiangsu Nhwa Pharmaceutical Co. Ltd. Use of 3-[(benzo[d][1 3]dioxolan-4-yl)-oxy]-3-aryl propylamine compound in preparation of drug for treating sexual dysfunction. WO 2025098307; 2024."},{"key":"e_1_3_3_48_1","doi-asserted-by":"crossref","unstructured":"Bell AS Palmer MJ. Chapter 8: the discovery of the long-acting PDE5 inhibitor PF-489791 for the treatment of pulmonary hypertension. In: Barrish J Carter P Cheng P Zahler R editors. Accounts in drug discovery. London: The Royal Society of Chemistry; 2010.","DOI":"10.1039\/9781849731980-00166"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.132225"},{"issue":"3","key":"e_1_3_3_50_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41401-020-0447-x","article-title":"Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor","volume":"42","author":"Tian QQ","year":"2021","unstructured":"Tian QQ, Zhu YT, Diao XX, Zhang XL, Xu YC, Jiang XR, Shen JS, Wang Z, Zhong DF. Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. Acta Pharmacol Sin. 2021;42(3):482\u2013490.","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"e_1_3_3_51_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2023.2242768","article-title":"Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments","volume":"32","author":"Melchiode Z","year":"2023","unstructured":"Melchiode Z, Nguyen T, Dawood O, Bobo GA, Hellstrom WJG. Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments. Expert Opin Investig Drugs. 2023;32(7):635\u2013642.","journal-title":"Expert Opin Investig Drugs"},{"key":"e_1_3_3_52_1","unstructured":"Zhang N Zhong R. Compound for inhibiting type 5 phosphodiesterase and preparation method thereof. US20130116265A1; 2013."},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.117014"},{"key":"e_1_3_3_54_1","unstructured":"S.A. Grupo Almirall Prodesfarma. 8-Phenylxanthine derivatives and their use as phosphodiesterase inhibitors. WO1999062905; 1999."},{"issue":"10","key":"e_1_3_3_55_1","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1743-6109.2011.02382.x","article-title":"Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature","volume":"8","author":"Azzouni F","year":"2011","unstructured":"Azzouni F, Abu Samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894\u20132903.","journal-title":"J Sex Med"},{"issue":"5","key":"e_1_3_3_56_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lary.21450","article-title":"Viagra deafness\u2014sensorineural hearing loss and phosphodiesterase-5 inhibitors","volume":"121","author":"Khan AS","year":"2011","unstructured":"Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness\u2014sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011;121(5):1049\u20131054.","journal-title":"Laryngoscope"},{"issue":"3","key":"e_1_3_3_57_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2003.11.010","article-title":"Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction","volume":"45","author":"Montorsi F","year":"2004","unstructured":"Montorsi F, Verheyden B, Meuleman E, J\u00fcnemann KP, Moncada I, Valiquette L, Casab\u00e9 A, Pacheco C, Denne J, Knight J, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45(3):339\u2013345.","journal-title":"Eur Urol"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2420"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2304"},{"issue":"12","key":"e_1_3_3_60_1","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1021\/jm060113e","article-title":"A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability","volume":"49","author":"Allerton CM","year":"2006","unstructured":"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, et al. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem. 2006;49(12):3581\u20133594.","journal-title":"J Med Chem"},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","first-page":"103257","DOI":"10.1016\/j.bioorg.2019.103257","article-title":"Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction","volume":"92","author":"Reddy GL","year":"2019","unstructured":"Reddy GL, Dar MI, Hudwekar AD, Mahajan P, Nargotra A, Baba AM, Nandi U, Wazir P, Singh G, Vishwakarma RA, et al. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction. Bioorg Chem. 2019;92:103257.","journal-title":"Bioorg Chem"},{"issue":"4","key":"e_1_3_3_62_1","doi-asserted-by":"crossref","first-page":"e202200707","DOI":"10.1002\/cbdv.202200707","article-title":"Pyrazolopyrimidinone based selective inhibitors of PDE5 for the treatment of erectile dysfunction","volume":"20","author":"Hudwekar AD","year":"2023","unstructured":"Hudwekar AD, Kotwal P, Dar MI, Balgotra S, Dogra A, Kour J, Chobe SS, Nandi U, Hussain Syed S, Sawant SD. Pyrazolopyrimidinone based selective inhibitors of PDE5 for the treatment of erectile dysfunction. Chem Biodivers. 2023;20(4):e202200707.","journal-title":"Chem Biodivers"},{"issue":"17","key":"e_1_3_3_63_1","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1016\/j.bmcl.2013.06.062","article-title":"Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5","volume":"23","author":"Gong X","year":"2013","unstructured":"Gong X, Wang G, Ren J, Liu Z, Wang Z, Chen T, Yang X, Jiang X, Shen J, Jiang H, et al. Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5. Bioorg Med Chem Lett. 2013;23(17):4944\u20134947.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bmcl.2018.11.043","article-title":"Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5","volume":"29","author":"Pobsuk N","year":"2019","unstructured":"Pobsuk N, Paracha TU, Chaichamnong N, Salaloy N, Suphakun P, Hannongbua S, Choowongkomon K, Pekthong D, Chootip K, Ingkaninan K, et al. Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5. Bioorg Med Chem Lett. 2019;29(2):267\u2013270.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000081"},{"key":"e_1_3_3_66_1","doi-asserted-by":"crossref","first-page":"104352","DOI":"10.1016\/j.bioorg.2020.104352","article-title":"Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy","volume":"105","author":"Ibrahim TS","year":"2020","unstructured":"Ibrahim TS, Hawwas MM, Taher ES, Alhakamy NA, Alfaleh MA, Elagawany M, Elgendy B, Zayed GM, Mohamed MFA, Abdel-Samii ZK, et al. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. Bioorg Chem. 2020;105:104352.","journal-title":"Bioorg Chem"},{"key":"e_1_3_3_67_1","doi-asserted-by":"crossref","first-page":"134216","DOI":"10.1016\/j.molstruc.2022.134216","article-title":"Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity","volume":"1272","author":"Nemr MTM","year":"2023","unstructured":"Nemr MTM, Teleb M, AboulMagd AM, El-Naggar ME, Gouda N, Abdel-Ghany AA, Elshaier YAMM. Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity. J Mol Struct. 2023;1272:134216.","journal-title":"J Mol Struct"},{"issue":"7","key":"e_1_3_3_68_1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/jm0155042","article-title":"Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction","volume":"44","author":"Yu G","year":"2001","unstructured":"Yu G, Mason HJ, Wu X, Wang J, Chong S, Dorough G, Henwood A, Pongrac R, Seliger L, He B, et al. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J Med Chem. 2001;44(7):1025\u20131027.","journal-title":"J Med Chem"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0256068"},{"issue":"19","key":"e_1_3_3_70_1","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1021\/acs.jmedchem.6b00908","article-title":"Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"59","author":"Rabal O","year":"2016","unstructured":"Rabal O, S\u00e1nchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, P\u00e9rez-Gonz\u00e1lez M, Garc\u00eda-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, S\u00e1ez E, Espelosin M, et al. Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer\u2019s disease. J Med Chem. 2016;59(19):8967\u20139004.","journal-title":"J Med Chem"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.03.005"},{"issue":"10","key":"e_1_3_3_72_1","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.bmcl.2009.03.125","article-title":"2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6","volume":"19","author":"Duan H","year":"2009","unstructured":"Duan H, Zheng J, Lai Q, Liu Z, Tian G, Wang Z, Li J, Shen J. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6. Bioorg Med Chem Lett. 2009;19(10):2777\u20132779.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301159y"},{"issue":"10","key":"e_1_3_3_74_1","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.jmedchem.9b00123","article-title":"Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension","volume":"62","author":"Wang Z","year":"2019","unstructured":"Wang Z, Jiang X, Zhang X, Tian G, Yang R, Wu J, Zou X, Liu Z, Yang X, Wu C, et al. Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension. J Med Chem. 2019;62(10):4979\u20134990.","journal-title":"J Med Chem"},{"issue":"4","key":"e_1_3_3_75_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejmech.2009.10.046","article-title":"Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective","volume":"45","author":"Abadi AH","year":"2010","unstructured":"Abadi AH, Gary BD, Tinsley HN, Piazza GA, Abdel-Halim M. Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem. 2010;45(4):1278\u20131286.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"e_1_3_3_76_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ardp.201200334","article-title":"Design of novel \u03b2-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors","volume":"346","author":"El-Gamil DS","year":"2013","unstructured":"El-Gamil DS, Ahmed NS, Gary BD, Piazza GA, Engel M, Hartmann RW, Abadi AH. Design of novel \u03b2-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors. Arch Pharm. 2013;346(1):23\u201333.","journal-title":"Arch Pharm"},{"issue":"3","key":"e_1_3_3_77_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ardp.201000236","article-title":"Design, synthesis and structure\u2013activity relationship of functionalized tetrahydro-\u03b2-carboline derivatives as novel PDE5 inhibitors","volume":"344","author":"Ahmed NS","year":"2011","unstructured":"Ahmed NS, Gary BD, Tinsley HN, Piazza GA, Laufer S, Abadi AH. Design, synthesis and structure\u2013activity relationship of functionalized tetrahydro-\u03b2-carboline derivatives as novel PDE5 inhibitors. Arch Pharm. 2011;344(3):149\u2013157.","journal-title":"Arch Pharm"},{"key":"e_1_3_3_78_1","doi-asserted-by":"crossref","first-page":"103742","DOI":"10.1016\/j.bioorg.2020.103742","article-title":"Extending the use of tadalafil scaffold: development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors","volume":"98","author":"ElHady AK","year":"2020","unstructured":"ElHady AK, Shih SP, Chen YC, Liu YC, Ahmed NS, Keeton AB, Piazza GA, Engel M, Abadi AH, Abdel-Halim M. Extending the use of tadalafil scaffold: development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. Bioorg Chem. 2020;98:103742.","journal-title":"Bioorg Chem"},{"key":"e_1_3_3_79_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ejmech.2018.09.028","article-title":"Discovery of furyl\/thienyl \u03b2-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect","volume":"158","author":"Zheng H","year":"2018","unstructured":"Zheng H, Wu Y, Sun B, Cheng C, Qiao Y, Jiang Y, Zhao S, Xie Z, Tan J, Lou H. Discovery of furyl\/thienyl \u03b2-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect. Eur J Med Chem. 2018;158:767\u2013780.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"e_1_3_3_80_1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1021\/acschemneuro.8b00014","article-title":"Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5)","volume":"9","author":"Ni W","year":"2018","unstructured":"Ni W, Wang H, Li X, Zheng X, Wang M, Zhang J, Gong Q, Ling D, Mao F, Zhang H, et al. Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5). ACS Chem Neurosci. 2018;9(7):1625\u20131636.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"e_1_3_3_81_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acschemneuro.7b00345","article-title":"Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer\u2019s disease","volume":"9","author":"Mao F","year":"2018","unstructured":"Mao F, Wang H, Ni W, Zheng X, Wang M, Bao K, Ling D, Li X, Xu Y, Zhang H, et al. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci. 2018;9(2):328\u2013345.","journal-title":"ACS Chem Neurosci"},{"issue":"17","key":"e_1_3_3_82_1","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.1021\/acs.jmedchem.3c01044","article-title":"Identification of novel quinolin-2(1H)-ones as phosphodiesterase 1 inhibitors for the treatment of inflammatory bowel disease","volume":"66","author":"Zhang B","year":"2023","unstructured":"Zhang B, Yang YY, Zhao ZJ, Liu RD, Feng LL, Jiang MY, Yuan Y, Huang S, Li Z, Wang Q, et al. Identification of novel quinolin-2(1H)-ones as phosphodiesterase 1 inhibitors for the treatment of inflammatory bowel disease. J Med Chem. 2023;66(17):12468\u201312478.","journal-title":"J Med Chem"},{"issue":"24","key":"e_1_3_3_83_1","doi-asserted-by":"crossref","first-page":"22134","DOI":"10.1021\/acs.jmedchem.4c02123","article-title":"Discovery and optimization of dihydroquinolin-2(1H)-ones as novel highly selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension","volume":"67","author":"Zhang B","year":"2024","unstructured":"Zhang B, Zou ZK, Cai JF, Tan WM, Chen JW, Li WE, Liang JN, Wu WP, Wang G, Ruan XH, et al. Discovery and optimization of dihydroquinolin-2(1H)-ones as novel highly selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Chem. 2024;67(24):22134\u201322144.","journal-title":"J Med Chem"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.12.090"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.12.009"},{"key":"e_1_3_3_86_1","doi-asserted-by":"crossref","first-page":"129409","DOI":"10.1016\/j.bmcl.2023.129409","article-title":"Optimizing metabolic stability of phosphodiesterase 5 inhibitors: discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity","volume":"92","author":"Zuccarello E","year":"2023","unstructured":"Zuccarello E, Zhang H, Acquarone E, Pham D, Staniszewski A, Deng SX, Landry DW, Arancio O, Fiorito J. Optimizing metabolic stability of phosphodiesterase 5 inhibitors: discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity. Bioorg Med Chem Lett. 2023;92:129409.","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"e_1_3_3_87_1","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.7b00979","article-title":"Identification of a novel 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine analogue as a potent phosphodiesterase 5 inhibitor with improved aqueous solubility for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Fiorito J","year":"2017","unstructured":"Fiorito J, Vendome J, Saeed F, Staniszewski A, Zhang H, Yan S, Deng SX, Arancio O, Landry DW. Identification of a novel 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine analogue as a potent phosphodiesterase 5 inhibitor with improved aqueous solubility for the treatment of Alzheimer\u2019s disease. J Med Chem. 2017;60(21):8858\u20138875.","journal-title":"J Med Chem"},{"issue":"6","key":"e_1_3_3_88_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acsmedchemlett.5c00108","article-title":"Discovery of indole-based PDE5 inhibitors: synthesis and pharmacological evaluation","volume":"16","author":"Park SY","year":"2025","unstructured":"Park SY, Pham D, Shukla P, Edward J, John R, Li A, Hadjiargyrou M, Mori M, Zuccarello E, Arancio O, et al. Discovery of indole-based PDE5 inhibitors: synthesis and pharmacological evaluation. ACS Med Chem Lett. 2025;16(6):1058\u20131065.","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"e_1_3_3_89_1","doi-asserted-by":"crossref","first-page":"111236","DOI":"10.1016\/j.cclet.2025.111236","article-title":"Plasma metabolites-based drug design: discovery of novel and highly selective phosphodiesterase 5 inhibitors","volume":"37","author":"Wu D","year":"2025","unstructured":"Wu D, Ma Q, Chen Y, Yang G, Zhang F, Jiang M, Wang X, Liu X, Zhou Q, Huang Y, et al. Plasma metabolites-based drug design: discovery of novel and highly selective phosphodiesterase 5 inhibitors. Chin Chem Lett. 2025;37(5):111236.","journal-title":"Chin Chem Lett"},{"issue":"1","key":"e_1_3_3_90_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2014.02.013","article-title":"Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c] pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure","volume":"89","author":"Shang NN","year":"2014","unstructured":"Shang NN, Shao YX, Cai YH, Guan M, Huang M, Cui W, He L, Yu YJ, Huang L, Li Z, et al. Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c] pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochem Pharmacol. 2014;89(1):86\u201398.","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"e_1_3_3_91_1","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1021\/acs.jmedchem.7b00523","article-title":"Discovery and optimization of chromeno[2,3-c]pyrrol-9(2H)-ones as novel selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension","volume":"60","author":"Wu D","year":"2017","unstructured":"Wu D, Zhang T, Chen Y, Huang Y, Geng H, Yu Y, Zhang C, Lai Z, Wu Y, Guo X, et al. Discovery and optimization of chromeno[2,3-c]pyrrol-9(2H)-ones as novel selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Chem. 2017;60(15):6622\u20136637.","journal-title":"J Med Chem"},{"issue":"18","key":"e_1_3_3_92_1","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/acs.jmedchem.8b01209","article-title":"Optimization of chromeno[2,3-c]pyrrol-9(2H)-ones as highly potent, selective, and orally bioavailable PDE5 inhibitors: structure\u2013activity relationship, X-ray crystal structure, and pharmacodynamic effect on pulmonary arterial hypertension","volume":"61","author":"Wu D","year":"2018","unstructured":"Wu D, Huang Y, Chen Y, Huang YY, Geng H, Zhang T, Zhang C, Li Z, Guo L, Chen J, et al. Optimization of chromeno[2,3-c]pyrrol-9(2H)-ones as highly potent, selective, and orally bioavailable PDE5 inhibitors: structure\u2013activity relationship, X-ray crystal structure, and pharmacodynamic effect on pulmonary arterial hypertension. J Med Chem. 2018;61(18):8468\u20138473.","journal-title":"J Med Chem"},{"issue":"3","key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.apsb.2021.09.027","article-title":"Free energy perturbation (FEP)-guided scaffold hopping","volume":"12","author":"Wu D","year":"2022","unstructured":"Wu D, Zheng X, Liu R, Li Z, Jiang Z, Zhou Q, Huang Y, Wu XN, Zhang C, Huang YY, et al. Free energy perturbation (FEP)-guided scaffold hopping. Acta Pharm Sin B. 2022;12(3):1351\u20131362.","journal-title":"Acta Pharm Sin B"},{"issue":"14","key":"e_1_3_3_94_1","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/jm9608467","article-title":"Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity","volume":"40","author":"Ahn HS","year":"1997","unstructured":"Ahn HS, Bercovici A, Boykow G, Bronnenkant A, Chackalamannil S, Chow J, Cleven R, Cook J, Czarniecki M, Domalski C, et al. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem. 1997;40(14):2196\u20132210.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_3_95_1","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.bmcl.2005.02.083","article-title":"Optimization of purine based PDE1\/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED","volume":"15","author":"Boyle CD","year":"2005","unstructured":"Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, et al. Optimization of purine based PDE1\/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. Bioorg Med Chem Lett. 2005;15(9):2365\u20132369.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_96_1","doi-asserted-by":"crossref","first-page":"115893","DOI":"10.1016\/j.ejmech.2023.115893","article-title":"Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors","volume":"262","author":"Liu J","year":"2023","unstructured":"Liu J, Zhang X, Chen G, Shao Q, Zou Y, Li Z, Su H, Li M, Xu Y. Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors. Eur J Med Chem. 2023;262:115893.","journal-title":"Eur J Med Chem"},{"issue":"13","key":"e_1_3_3_97_1","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/jm000558h","article-title":"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives","volume":"44","author":"Ukita T","year":"2001","unstructured":"Ukita T, Nakamura Y, Kubo A, Yamamoto Y, Moritani Y, Saruta K, Higashijima T, Kotera J, Takagi M, Kikkawa K, et al. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. J Med Chem. 2001;44(13):2204\u20132218.","journal-title":"J Med Chem"},{"issue":"14","key":"e_1_3_3_98_1","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0960-894X(03)00440-2","article-title":"1,7- and 2,7-Naphthyridine derivatives as potent and highly specific PDE5 inhibitors","volume":"13","author":"Ukita T","year":"2003","unstructured":"Ukita T, Nakamura Y, Kubo A, Yamamoto Y, Moritani Y, Saruta K, Higashijima T, Kotera J, Fujishige K, Takagi M, et al. 1,7- and 2,7-Naphthyridine derivatives as potent and highly specific PDE5 inhibitors. Bioorg Med Chem Lett. 2003;13(14):2341\u20132345.","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"e_1_3_3_99_1","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1016\/j.bmcl.2014.09.082","article-title":"Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation","volume":"24","author":"Sakamoto T","year":"2014","unstructured":"Sakamoto T, Koga Y, Hikota M, Matsuki K, Murakami M, Kikkawa K, Fujishige K, Kotera J, Omori K, Morimoto H, et al. Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation. Bioorg Med Chem Lett. 2014;24(22):5175\u20135180.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_100_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejmech.2019.05.026","article-title":"Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model","volume":"177","author":"Bollenbach M","year":"2019","unstructured":"Bollenbach M, Lugnier C, Kremer M, Salvat E, Megat S, Bihel F, Bourguignon JJ, Barrot M, Schmitt M. Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. Eur J Med Chem. 2019;177:269\u2013290.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"e_1_3_3_101_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-3565(25)21767-0","article-title":"Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation","volume":"228","author":"Hagiwara M","year":"1984","unstructured":"Hagiwara M, Endo T, Kanayama T, Hidaka H. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J Pharmacol Exp Ther. 1984;228(2):467\u2013471.","journal-title":"J Pharmacol Exp Ther"},{"issue":"18","key":"e_1_3_3_102_1","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1021\/jm970815r","article-title":"4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5","volume":"41","author":"Watanabe N","year":"1998","unstructured":"Watanabe N, Kabasawa Y, Takase Y, Matsukura M, Miyazaki K, Ishihara H, Kodama K, Adachi H. 4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. J Med Chem. 1998;41(18):3367\u20133372.","journal-title":"J Med Chem"},{"issue":"13","key":"e_1_3_3_103_1","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/jm9905054","article-title":"4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5","volume":"43","author":"Watanabe N","year":"2000","unstructured":"Watanabe N, Adachi H, Takase Y, Ozaki H, Matsukura M, Miyazaki K, Ishibashi K, Ishihara H, Kodama K, Nishino M, et al. 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. J Med Chem. 2000;43(13):2523\u20132529.","journal-title":"J Med Chem"},{"issue":"2","key":"e_1_3_3_104_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0022-3565(24)34959-6","article-title":"Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats","volume":"290","author":"Kodama K","year":"1999","unstructured":"Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 1999;290(2):748\u2013752.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"e_1_3_3_105_1","first-page":"L225","article-title":"E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats","volume":"277","author":"Hanasato N","year":"1999","unstructured":"Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol. 1999;277(2):L225\u2013L232.","journal-title":"Am J Physiol"},{"issue":"15","key":"e_1_3_3_106_1","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1016\/j.bmcl.2009.06.012","article-title":"Identification, synthesis and SAR of amino substituted pyrido[3,2-b]pyrazinones as potent and selective PDE5 inhibitors","volume":"19","author":"Owen DR","year":"2009","unstructured":"Owen DR, Walker JK, Jon Jacobsen E, Freskos JN, Hughes RO, Brown DL, Bell AS, Brown DG, Phillips C, Mischke BV, et al. Identification, synthesis and SAR of amino substituted pyrido[3,2-b]pyrazinones as potent and selective PDE5 inhibitors. Bioorg Med Chem Lett. 2009;19(15):4088\u20134091.","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"e_1_3_3_107_1","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.bmcl.2009.06.004","article-title":"Investigation of aminopyridiopyrazinones as PDE5 inhibitors: evaluation of modifications to the central ring system","volume":"19","author":"Hughes RO","year":"2009","unstructured":"Hughes RO, Walker JK, Cubbage JW, Fobian YM, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Owen DR, Jacobsen EJ, et al. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: evaluation of modifications to the central ring system. Bioorg Med Chem Lett. 2009;19(15):4092\u20134096.","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"e_1_3_3_108_1","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1016\/j.bmcl.2009.07.019","article-title":"Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one","volume":"19","author":"Hughes RO","year":"2009","unstructured":"Hughes RO, Walker JK, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Jacobsen EJ, Cubbage JW, Fobian YM, Owen DR, et al. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. Bioorg Med Chem Lett. 2009;19(17):5209\u20135213.","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"e_1_3_3_109_1","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1016\/j.bmcl.2011.08.106","article-title":"Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region","volume":"21","author":"Hughes RO","year":"2011","unstructured":"Hughes RO, Maddux T, Joseph Rogier D, Lu S, Walker JK, Jon Jacobsen E, Rumsey JM, Zheng Y, Macinnes A, Bond BR, et al. Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. Bioorg Med Chem Lett. 2011;21(21):6348\u20136352.","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"e_1_3_3_110_1","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1021\/acs.jmedchem.0c00983","article-title":"Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket","volume":"63","author":"Zhang T","year":"2020","unstructured":"Zhang T, Lai Z, Yuan S, Huang YY, Dong G, Sheng C, Ke H, Luo HB. Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket. J Med Chem. 2020;63(17):9828\u20139837.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_3_111_1","doi-asserted-by":"crossref","first-page":"127097","DOI":"10.1016\/j.bmcl.2020.127097","article-title":"Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer\u2019s disease","volume":"30","author":"Huang XF","year":"2020","unstructured":"Huang XF, Dong YH, Wang JH, Ke HM, Song GQ, Xu DF. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett. 2020;30(9):127097.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"e_1_3_3_112_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/molecules28020840","article-title":"Novel 9-benzylaminoacridine derivatives as dual inhibitors of phosphodiesterase 5 and topoisomerase II for the treatment of colon cancer","volume":"28","author":"Ammar L","year":"2023","unstructured":"Ammar L, Lin HY, Shih SP, Tsai TN, Syu YT, Abdel-Halim M, Hwang TL, Abadi AH. Novel 9-benzylaminoacridine derivatives as dual inhibitors of phosphodiesterase 5 and topoisomerase II for the treatment of colon cancer. Molecules. 2023;28(2):840.","journal-title":"Molecules"},{"issue":"5","key":"e_1_3_3_113_1","doi-asserted-by":"crossref","first-page":"e1800018","DOI":"10.1002\/ardp.201800018","article-title":"Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors","volume":"351","author":"El-Sharkawy LY","year":"2018","unstructured":"El-Sharkawy LY, El-Sakhawy RA, Abdel-Halim M, Lee K, Piazza GA, Ducho C, Hartmann RW, Abadi AH. Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors. Arch Pharm. 2018;351(5):e1800018.","journal-title":"Arch Pharm"},{"key":"e_1_3_3_114_1","doi-asserted-by":"crossref","unstructured":"Bremner JB Sengpracha W Southwel l Bourke C Skelton BW White AH. A revised structure for the alkaloid tribulusterine from Tribulus terrestris L. Aust. J. Chem. 2004;57:273\u2013276.","DOI":"10.1071\/CH03230"},{"issue":"19","key":"e_1_3_3_115_1","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1021\/jm025545d","article-title":"Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction","volume":"45","author":"Sui Z","year":"2002","unstructured":"Sui Z, Guan J, Macielag MJ, Jiang W, Zhang S, Qiu Y, Kraft P, Bhattacharjee S, John TM, Haynes-Johnson D, et al. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction. J Med Chem. 2002;45(19):4094\u20134096.","journal-title":"J Med Chem"},{"issue":"50","key":"e_1_3_3_116_1","doi-asserted-by":"crossref","first-page":"29723","DOI":"10.1039\/D0RA05561A","article-title":"Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1\/COX-2 inhibitors","volume":"10","author":"Hussein AHM","year":"2020","unstructured":"Hussein AHM, Khames AA, El-Adasy AA, Atalla AA, Abdel-Rady M, Hassan MIA, Nemr MTM, Elshaier YAAM. Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1\/COX-2 inhibitors. RSC Adv. 2020;10(50):29723\u201329736.","journal-title":"RSC Adv"},{"key":"e_1_3_3_117_1","doi-asserted-by":"crossref","first-page":"104322","DOI":"10.1016\/j.bioorg.2020.104322","article-title":"Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors","volume":"104","author":"Abdel-Halim M","year":"2020","unstructured":"Abdel-Halim M, Tinsley H, Keeton AB, Weam M, Atta NH, Hammam MA, Hefnawy A, Hartmann RW, Engel M, Piazza GA, et al. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. Bioorg Chem. 2020;104:104322.","journal-title":"Bioorg Chem"},{"issue":"8","key":"e_1_3_3_118_1","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/acs.jmedchem.0c01120","article-title":"From celecoxib to a novel class of phosphodiesterase 5 inhibitors: trisubstituted pyrazolines as novel phosphodiesterase 5 inhibitors with extremely high potency and phosphodiesterase isozyme selectivity","volume":"64","author":"Abdel-Halim M","year":"2021","unstructured":"Abdel-Halim M, Sigler S, Racheed NAS, Hefnawy A, Fathalla RK, Hammam MA, Maher A, Maxuitenko Y, Keeton AB, Hartmann RW, et al. From celecoxib to a novel class of phosphodiesterase 5 inhibitors: trisubstituted pyrazolines as novel phosphodiesterase 5 inhibitors with extremely high potency and phosphodiesterase isozyme selectivity. J Med Chem. 2021;64(8):4462\u20134477.","journal-title":"J Med Chem"},{"issue":"2","key":"e_1_3_3_119_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17460441.2016.1272757","article-title":"The structural modification of natural products for novel drug discovery","volume":"12","author":"Yao H","year":"2017","unstructured":"Yao H, Liu J, Xu S, Zhu Z, Xu J. The structural modification of natural products for novel drug discovery. Expert Opin Drug Discov. 2017;12(2):121\u2013140.","journal-title":"Expert Opin Drug Discov"},{"key":"e_1_3_3_120_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.fitote.2015.04.012","article-title":"Insights into drug discovery from natural products through structural modification","volume":"103","author":"Chen J","year":"2015","unstructured":"Chen J, Li W, Yao H, Xu J. Insights into drug discovery from natural products through structural modification. Fitoterapia. 2015;103:231\u2013241.","journal-title":"Fitoterapia"},{"issue":"9","key":"e_1_3_3_121_1","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1002\/ptr.7099","article-title":"Natural products: a lead for drug discovery and development","volume":"35","author":"Chopra B","year":"2021","unstructured":"Chopra B, Dhingra AK. Natural products: a lead for drug discovery and development. Phytother Res. 2021;35(9):4660\u20134702.","journal-title":"Phytother Res"},{"issue":"17","key":"e_1_3_3_122_1","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0960-894X(02)00401-8","article-title":"A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5","volume":"12","author":"Shin HJ","year":"2002","unstructured":"Shin HJ, Kim HJ, Kwak JH, Chun HO, Kim JH, Park H, Kim DH, Lee YS. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002;12(17):2313\u20132316.","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_3_123_1","doi-asserted-by":"crossref","first-page":"105465","DOI":"10.1016\/j.fitote.2023.105465","article-title":"Flavonoids and prenylhydroquinones from the prepared folium of Epimedium sagittatum Maxim. and their inhibition against phosphodiesterase-5A","volume":"168","author":"Li J","year":"2023","unstructured":"Li J, He Y, Zheng X, Li S, Wu Y, Shi W, Pan K, Sun J, Wang Z, Xu J, et al. Flavonoids and prenylhydroquinones from the prepared folium of Epimedium sagittatum Maxim. and their inhibition against phosphodiesterase-5A. Fitoterapia. 2023;168:105465.","journal-title":"Fitoterapia"},{"issue":"9","key":"e_1_3_3_124_1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/np800049y","article-title":"Potent inhibition of human phosphodiesterase-5 by icariin derivatives","volume":"71","author":"Dell\u2019Agli M","year":"2008","unstructured":"Dell\u2019Agli M, Galli GV, Dal Cero E, Belluti F, Matera R, Zironi E, Pagliuca G, Bosisio E. Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008;71(9):1513\u20131517.","journal-title":"J Nat Prod"},{"issue":"1","key":"e_1_3_3_125_1","first-page":"79","article-title":"Phenanthrenes from Eulophia macrobulbon as novel phosphodiesterase-5 inhibitors","volume":"12","author":"Temkifthawon P","year":"2017","unstructured":"Temkifthawon P, Changwichit K, Khorana N, Viyoch J, Suwanborirux K, Ingkaninan K. Phenanthrenes from Eulophia macrobulbon as novel phosphodiesterase-5 inhibitors. Nat Prod Commun. 2017;12(1):79\u201382.","journal-title":"Nat Prod Commun"},{"issue":"1","key":"e_1_3_3_126_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jphp.12302","article-title":"Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries","volume":"67","author":"Kruangtip O","year":"2015","unstructured":"Kruangtip O, Chootip K, Temkitthawon P, Changwichit K, Chuprajob T, Changtam C, Suksamrarn A, Khorana N, Scholfield CN, Ingkaninan K. Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries. J Pharm Pharmacol. 2015;67(1):87\u201395.","journal-title":"J Pharm Pharmacol"},{"key":"e_1_3_3_127_1","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.fitote.2023.105780","article-title":"Ent-labdane-type diterpene glycosides obtained from Rubus chingii Hu and their inhibitory effects on PDE5A activity","volume":"173","author":"Yu JD","year":"2024","unstructured":"Yu JD, Wang JY, Liu JY, Xu YC, Zhang X, Du J, Wu XH, Chen L, Wu YC, Li YM. Ent-labdane-type diterpene glycosides obtained from Rubus chingii Hu and their inhibitory effects on PDE5A activity. Fitoterapia. 2024;173:105780.","journal-title":"Fitoterapia"},{"issue":"11","key":"e_1_3_3_128_1","doi-asserted-by":"crossref","first-page":"9397","DOI":"10.3390\/ijms24119397","article-title":"A non-systemic phosphodiesterase-5 inhibitor suppresses colon proliferation in mice","volume":"24","author":"Lee A","year":"2023","unstructured":"Lee A, Lebedyeva I, Zhi W, Senthil V, Cheema H, Brands MW, Bush W, Lambert NA, Snipes M, Browning DD. A non-systemic phosphodiesterase-5 inhibitor suppresses colon proliferation in mice. Int J Mol Sci. 2023;24(11):9397.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"e_1_3_3_129_1","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1021\/jm200644r","article-title":"Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors","volume":"54","author":"Xu Z","year":"2011","unstructured":"Xu Z, Liu Z, Chen T, Chen T, Wang Z, Tian G, Shi J, Wang X, Lu Y, Yan X, et al. Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. J Med Chem. 2011;54(15):5607\u20135611.","journal-title":"J Med Chem"},{"issue":"3","key":"e_1_3_3_130_1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/molecules30030588","article-title":"Molecular dynamics-assisted discovery of novel phosphodiesterase-5 inhibitors targeting a unique allosteric pocket","volume":"30","author":"Luo W","year":"2025","unstructured":"Luo W, Liu R, Cai X, Zhou Q, Zhang C. Molecular dynamics-assisted discovery of novel phosphodiesterase-5 inhibitors targeting a unique allosteric pocket. Molecules. 2025;30(3):588.","journal-title":"Molecules"},{"key":"e_1_3_3_131_1","doi-asserted-by":"crossref","first-page":"1400886","DOI":"10.3389\/fchem.2024.1400886","article-title":"Mechanism investigation of highly selective inhibitors toward phosphodiesterase 5 and 6 via the in vitro calculation and simulation","volume":"12","author":"Qu L","year":"2024","unstructured":"Qu L, Sun K, Jiang Z, Wang T, Chen L, Shen C, Gu R. Mechanism investigation of highly selective inhibitors toward phosphodiesterase 5 and 6 via the in vitro calculation and simulation. Front Chem. 2024;12:1400886.","journal-title":"Front Chem"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2687714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2687714","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2687714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:13:06Z","timestamp":1783008786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2687714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2687714"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2687714","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2687714"}}